204 related articles for article (PubMed ID: 17023229)
1. Development of a pharmacokinetic/pharmacodynamic model for carvedilol to predict beta1-blockade in patients with congestive heart failure.
Tenero DM; Henderson LS; Campanile AM; Baidoo CA; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):27L-31L. PubMed ID: 17023229
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of a new controlled-release formulation of carvedilol.
Tenero DM; Henderson LS; Baidoo CA; Harter AH; Campanile AM; Danoff TM; Boyle D
Am J Cardiol; 2006 Oct; 98(7A):5L-16L. PubMed ID: 17023227
[TBL] [Abstract][Full Text] [Related]
5. COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
Greenberg BH; Mehra M; Teerlink JR; Ordronneau P; McCollum D; Gilbert EM
Am J Cardiol; 2006 Oct; 98(7A):53L-59L. PubMed ID: 17023233
[TBL] [Abstract][Full Text] [Related]
6. Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial.
Udelson JE; Pressler SJ; Sackner-Bernstein J; Massaro J; Ordronneau P; Lukas MA; Hauptman PJ
J Card Fail; 2009 Jun; 15(5):385-93. PubMed ID: 19477398
[TBL] [Abstract][Full Text] [Related]
7. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of CASPER: compliance and quality of life study comparing once-daily carvedilol CR and twice-daily carvedilol IR in patients with heart failure.
Hauptman PJ; Pressler SJ; Sackner-Bernstein J; Ordronneau P; Udelson JE;
Am J Cardiol; 2006 Oct; 98(7A):60L-66L. PubMed ID: 17023234
[TBL] [Abstract][Full Text] [Related]
9. Role of carvedilol controlled-release in cardiovascular disease.
Fonarow GC
Expert Rev Cardiovasc Ther; 2009 May; 7(5):483-98. PubMed ID: 19419256
[TBL] [Abstract][Full Text] [Related]
10. Controlled-release carvedilol in the treatment of essential hypertension.
Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
[TBL] [Abstract][Full Text] [Related]
11. Design of a novel controlled-release formulation of carvedilol: pharmacology and clinical aspects. Introduction.
Sica DA
Am J Cardiol; 2006 Oct; 98(7A):1L-4L. PubMed ID: 17023226
[No Abstract] [Full Text] [Related]
12. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.
Othman AA; Tenero DM; Boyle DA; Eddington ND; Fossler MJ
AAPS J; 2007 Jun; 9(2):E208-18. PubMed ID: 17614362
[TBL] [Abstract][Full Text] [Related]
13. Controlled-release carvedilol: a concluding perspective.
Packer M
Am J Cardiol; 2006 Oct; 98(7A):67L-69L. PubMed ID: 17023235
[No Abstract] [Full Text] [Related]
14. Carvedilol: use in chronic heart failure.
Doughty RN; White HD
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):21-31. PubMed ID: 17187454
[TBL] [Abstract][Full Text] [Related]
15. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
[TBL] [Abstract][Full Text] [Related]
16. Is urethane-chloralose anaesthesia appropriate for pharmacokinetic-pharmacodynamic assessment? Studies with carvedilol.
Bertera FM; Di Verniero CA; Mayer MA; Bramuglia GF; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2009; 59(1):13-20. PubMed ID: 18973819
[TBL] [Abstract][Full Text] [Related]
17. Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits.
Spaeder J; Najjar SS; Gerstenblith G; Hefter G; Kern L; Palmer JG; Gottlieb SH; Kasper EK
Am Heart J; 2006 Apr; 151(4):844.e1-10. PubMed ID: 16569544
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure.
Talbert RL
Heart Fail Rev; 2004 Apr; 9(2):131-7. PubMed ID: 15516861
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
20. Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol.
Liu XY; Wang BJ; Yuan GY; Guo RC
Yao Xue Xue Bao; 2009 Apr; 44(4):406-11. PubMed ID: 19545060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
